SWP Financial LLC Invests $366,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

SWP Financial LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, Holdings Channel reports. The firm bought 7,652 shares of the biopharmaceutical company’s stock, valued at approximately $366,000.

Several other institutional investors have also recently bought and sold shares of HALO. GAMMA Investing LLC grew its stake in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares during the last quarter. Toth Financial Advisory Corp bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth about $57,000. FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at about $65,000. Park Place Capital Corp grew its position in Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,209 shares in the last quarter. Finally, CWM LLC increased its stake in Halozyme Therapeutics by 77.5% during the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 668 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $55.77 on Monday. The firm has a market cap of $7.10 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 0.42 and a beta of 1.24. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a 50 day moving average of $49.59 and a 200-day moving average of $54.23.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. JMP Securities raised their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, HC Wainwright raised their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.